Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ. Muriel C, et al. Among authors: fra j. Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0. Clin Transl Oncol. 2010. PMID: 20709657
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). Esteban E, et al. Among authors: fra j. Invest New Drugs. 2006 May;24(3):241-8. doi: 10.1007/s10637-005-2478-z. Invest New Drugs. 2006. PMID: 16096704 Clinical Trial.
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Esteban E, Villanueva N, Muñiz I, Fernández Y, Fra J, Luque M, Jiménez P, Llorente B, Capelan M, Vieitez JM, Estrada E, Buesa JM, Jiménez-Lacave A. Esteban E, et al. Among authors: fra j. Invest New Drugs. 2008 Feb;26(1):67-74. doi: 10.1007/s10637-007-9073-4. Epub 2007 Sep 5. Invest New Drugs. 2008. PMID: 17805486 Clinical Trial.
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ. Gonzalez EE, et al. Among authors: fra j. Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13. Invest New Drugs. 2011. PMID: 20464446 Clinical Trial.
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ. Crespo G, et al. Among authors: fra j. Int J Gynecol Cancer. 2011 Apr;21(3):478-85. doi: 10.1097/IGC.0b013e31820d738c. Int J Gynecol Cancer. 2011. PMID: 21436695 Clinical Trial.
Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer.
Esteban E, Fra J, Corral N, Valle M, Carrasco J, Sala M, Puerta J, Estrada E, Palacio I, Vieitez JM, Buesa JM, Lacave AJ. Esteban E, et al. Among authors: fra j. Invest New Drugs. 2002 Feb;20(1):73-82. doi: 10.1023/a:1014490417342. Invest New Drugs. 2002. PMID: 12003196 Clinical Trial.
42 results